Navigation Links
Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
Date:9/20/2010

PRINCETON, N.J., Sept. 20 /PRNewswire/ -- Signum Biosciences, Inc. was recently awarded two Small Business Innovation Research (SBIR) Phase I grants by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the NIH, totaling over $684,000 for development of novel G-protein coupled receptor (GPCR) modulating therapeutics designed to treat common skin disorders.  

Through the first SBIR grant, Signum will develop anti-inflammatory agents to reduce chronic redness (erythema) associated with eczema, atopic dermatitis, and rosacea. Access to more effective therapies is of significant importance to a large patient population suffering from chronic skin disease. Signum's Signal Transduction Modulator (STM) technology has already demonstrated significant reduction of redness in a double-blinded placebo controlled clinical study.

A second SBIR grant was awarded to fund Signum's identification and development of multi-functional, safe, topical anti-acne therapeutics. Acne is the most common disorder of the human skin and affects up to 80% of individuals at some point in their lives. Signum's STM technology has shown potential to reduce both inflammation and infection associated with acne.  

"We are proud to be awarded additional grants by the NIH, further supporting our unique approach and scientific direction. Our objective continues to be development of our technology with the goal of improving quality of life for the large number of patients suffering from skin disease," stated Dr. Braham Shroot, Chief Executive Officer of Signum.  Signum has a history of successful grant funding including four NIH SBIRs for skin therapeutics totaling over $2.5M.  The company is currently in the second year of a two year $1.6 M phase II SBIR grant for the development of a rosacea therapeutic which will enter the clinic next year.  

About Signum Biosciences.

Signum Biosciences is a priv
'/>"/>

SOURCE Signum Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
2. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
3. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
10. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
11. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Calif. , Nov. 21, 2014 In ... and Performance Scrubs carried out a new product development ... industry,s very first "limited edition" lab coat , ... female professors of surgery in the world. The new ... its unisex predecessors, with a sleek envelope collar, vertical ...
(Date:11/21/2014)... Nov. 21, 2014  Heated dialogue in recent months ... from cancer treatments to Gilead,s new hepatitis C drug ... the world questioning what it means to put a ... And while drug pricing is one of ... from both a general business and ethical standpoint – ...
(Date:11/21/2014)... 2014 Clementia Pharmaceuticals, ... dass die Europäische Arzneimittel-Agentur (European Medicines ... Orphan-Medizinprodukt an Palovarotene vergeben hat, den ... von Fibrodysplasia ossificans progressiva (FOP). FOP ... Krankheit, die von schmerzhaften, wiederkehrenden Episoden ...
Breaking Medicine Technology:Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
(Date:11/21/2014)... -- Seeking to make it tougher for people to ... on Thursday approved a new hydrocodone tablet that,s designed ... by the brand name Vicodin -- is a powerful ... in dangerous addictions across the United States. The ... is an extended-release tablet to treat pain severe enough ...
(Date:11/21/2014)... they,ve mapped the genome -- the genetic "blueprint" -- of ... it might help others with this very rare infection. ... , the tapeworm was removed from the brain of a ... so rare worldwide and completely unexpected in this country that ... pulled out from the brain," study lead author Hayley Bennett, ...
(Date:11/21/2014)... November 21, 2014 Center for Autism ... titled “Massachusetts Insurance Funding for Autism Workshops” to help ... their way through the insurance coverage process. Parents ... law and the most effective ways to access coverage. ... 4 from 6-8:00 p.m. at 331 Montvale Ave., 5th ...
(Date:11/21/2014)... 21, 2014 Big Bud Farms announced ... episode of Innovations with Ed Begley Jr., airing via ... TBA. , Big Bud Farms, growers of legal medical ... and utilization of medical marijuana. , This segment of ... wide variety of products for medicating. Viewers will learn ...
(Date:11/21/2014)... 2014 Launched today on the iTunes ... all-in-one senior care coordination tool designed to make tracking ... and intuitive for family members and caregivers (e.g. physicians ... the family caregiver or home health aide providing care ... data, medical records, goals, schedules, and even final plans ...
Breaking Medicine News(10 mins):Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 3Health News:Ick! Tapeworm Infecting Man's Brain Yields Genetic Secrets 2Health News:Center for Autism and Related Disorders to Host Massachusetts Autism Insurance Workshops for Parents 2Health News:Big Bud Farms to be Featured in Upcoming Episode of Innovations with Ed Begley Jr. 2Health News:Comprehensive Senior Care Application Launched on Apple App Store 2
... LOS ANGELES, Nov. 8 Response Genetics, Inc.,(Nasdaq: ... development of molecular,diagnostic tests for cancer, today announced ... financial results in a press release on,Wednesday, November ... Response Genetics, Inc. ("RGI") is engaged in the ...
... EMPLOYERS(R) (NYSE: EIG ),a leading ... a,new partnership with the California Restaurant Association ... compensation insurance with a,special CRA membership discount. ... http://www.newscom.com/cgi-bin/prnh/20061030/LAM128LOGO ) "We are enthusiastic ...
... 8 DATATRAK International,Inc. (Nasdaq: DATA ), a ... the clinical trials industry, today reported its,operating results for ... For the three months ended September 30, 2007, ... net loss of $(3,506,000), or $(0.26),per share on a ...
... Resources on Partnership to Develop Rapid Molecular ... Tests for Healthcare-Associated Infections -, SAN DIEGO, Nov. 8 ... informed the Company it no longer intends to,fund the companies, ... The companies expect to formally terminate the,collaboration in the coming ...
... Approve Sale of Nabi ... Biologics to Biotest, ... today announced its third quarter,financial results. The company recorded a net ... September 29, 2007, which included,$7.5 million, or $0.12 per share, of ...
... Hispanic youth report better dental health habits than their non-Hispanic ... researchers at Columbia University Mailman School of Public Health. ... the Journal of Health Care for the Poor and Underserved, ... community in America. , The study, a snapshot of more ...
Cached Medicine News:Health News:Response Genetics to Announce Third Quarter 2007 Financial Results on Wednesday, November 14, 2007 2Health News:California Restaurant Association Chooses EMPLOYERS(R) as its New Provider of Choice for Members' Workers' Compensation Insurance Needs 2Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 2Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 3Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 4Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 5Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 6Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 7Health News:DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results 8Health News:3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration 2Health News:3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration 3Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 2Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 3Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 4Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 5Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 6Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 7Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 8Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 9Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 10Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 11Health News:Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting 12Health News:Study of minority New York City youth finds unequal burden of poor dental health 2
... and fabric specialty drapes for ... Steri-Drape absorbent prevention fabric creates ... strike-through reducing the need for ... Pack, Op tape, Hand towels, ...
... The table top design takes into ... and creates a flexible working environment for ... the alphamaxx can be matched exactly to ... top slide capability creates superior access for ...
... DePuy Mitek is the Market leader ... With ORTHOCORD Suture, DePuy Mitek has developed ... arthroscopic and open shoulder repair. ORTHOCORD Suture ... suture on the market. Most importantly, ORTHOCORD ...
... Now you can ... tactile sensitivity of the ... Free surgical gloves on ... Free gloves provide the ...
Medicine Products: